|
|
| | Kuguacin J Basic information |
| Product Name: | Kuguacin J | | Synonyms: | Kuguacin J;19-Norlanosta-5,23,25-triene-9-carboxaldehyde, 3,7-dihydroxy-, (3β,7β,9β,10α,23E)- | | CAS: | 1141453-65-7 | | MF: | C30H46O3 | | MW: | 454.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1141453-65-7.mol |  |
| | Kuguacin J Chemical Properties |
| Melting point | 166-169 °C | | Boiling point | 563.7±50.0 °C(Predicted) | | density | 1.07±0.1 g/cm3(Predicted) | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Powder | | pka | 13.73±0.70(Predicted) |
| | Kuguacin J Usage And Synthesis |
| Description | Kuguacin J exerts growth inhibition through G1 arrest and induction of apoptosis in androgen-dependent human prostate cancer, it is a promising candidate new antineoplastic and chemopreventive agent for androgen-dependent prostate cancer and carcinogenesis.
Kuguacin J modulates the function of P-glycoprotein (P-gp) by directly interacting at the drug-substrate-binding site, and it appears to be an effective inhibitor of P-gp activity in vitro and thus could be developed as an effective chemosensitizer to treat multidrug-resistant cancers. | | target | p21 | CDK | Bcl-2/Bax | Caspase | PARP | Androgen Receptor | p53 | P-gp |
| | Kuguacin J Preparation Products And Raw materials |
|